Gefapixant
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Gefapixant
- Accession Number
- DB15097
- Description
Gefapixant is under investigation in clinical trial NCT02397460 (Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Gefapixant (DB15097)
- Weight
- Average: 353.4
Monoisotopic: 353.115775286 - Chemical Formula
- C14H19N5O4S
- Synonyms
- Not Available
- External IDs
- AF-219
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- 6K6L7E3F1L
- CAS number
- 1015787-98-0
- InChI Key
- HLWURFKMDLAKOD-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19)
- IUPAC Name
- 5-[(2,4-diaminopyrimidin-5-yl)oxy]-2-methoxy-4-(propan-2-yl)benzene-1-sulfonamide
- SMILES
- COC1=C(C=C(OC2=CN=C(N)N=C2N)C(=C1)C(C)C)S(N)(=O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 58828660
- ChEMBL
- CHEMBL3716057
- ZINC
- ZINC000116342482
- PDBe Ligand
- AF9
- Wikipedia
- Gefapixant
- PDB Entries
- 5yve
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Chronic Cough (CC) 3 3 Recruiting Treatment Chronic Cough (CC) 1 3 Recruiting Treatment Coughing 2 2 Completed Treatment Asthma 1 2 Completed Treatment Chronic Cough (CC) 2 2 Completed Treatment Coughing / Idiopathic Pulmonary Fibrosis (IPF) 1 2 Completed Treatment Endometriosis related pain / Endometriosis-related Pain 1 2 Completed Treatment Idiopathic Pulmonary Fibrosis (IPF) 1 2 Completed Treatment Osteoarthritis of the Knee 1 2 Completed Treatment Refractory Chronic Cough 6
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.503 mg/mL ALOGPS logP 0.87 ALOGPS logP 0.86 ChemAxon logS -2.8 ALOGPS pKa (Strongest Acidic) 9.67 ChemAxon pKa (Strongest Basic) 6.76 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 7 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 156.44 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 91.44 m3·mol-1 ChemAxon Polarizability 34.62 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on May 20, 2019 08:49 / Updated on June 12, 2020 10:53